Abstract |
Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.
|
Authors | Edward M Sellers, Deborah B Leiderman |
Journal | Clinical pharmacology and therapeutics
(Clin Pharmacol Ther)
Vol. 103
Issue 4
Pg. 561-564
(04 2018)
ISSN: 1532-6535 [Electronic] United States |
PMID | 28836272
(Publication Type: Journal Article)
|
Copyright | © 2017 American Society for Clinical Pharmacology and Therapeutics. |
Chemical References |
|
Topics |
- Drug Approval
(methods)
- Drug Discovery
(ethics, methods)
- Hallucinogens
(pharmacology, therapeutic use)
- Humans
- Mental Disorders
(drug therapy)
- Patient Selection
- Risk Evaluation and Mitigation
|